PET: cerebral blood flow and glucose metabolism--pathophysiology and drug effects.
Theodore
W H
WH
Clinical Epilepsy Section, National Institutes of Health, Bethesda, Maryland, USA.
D000927:Anticonvulsants / Q000494:pharmacology* / Q000627:therapeutic use; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D004833:Epilepsy, Temporal Lobe / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000503:physiopathology; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D008657:Metabolic Clearance Rate / Q000187:drug effects / Q000502:physiology; D013702:Temporal Lobe / Q000098:blood supply / Q000187:drug effects* / Q000503:physiopathology; D014055:Tomography, Emission-Computed / Q000379:methods*; D014635:Valproic Acid / Q000494:pharmacology / Q000627:therapeutic use; D020888:Vigabatrin / Q000494:pharmacology / Q000627:therapeutic use
D000927:Anticonvulsants; D014635:Valproic Acid; D020888:Vigabatrin; D005947:Glucose